Anti-angiogenic treatment and colorectal cancer;Traitement anti-angiogénique et cancer colorectal

Bulletin du Cancer

Volumn 94, Issue SPECIAL, 2007, Pages

  André, Thierry ^a   Tournigand, Christophe ^b,c   Abbas, Fadi ^a   Louvet, Christophe ^b,c   De Gramont, Aimery ^b,c  

^a HÔPITAL TENON   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c GERCOR   (France)

Author keywords

Anti angiogenic; Bevacizumab; Colorectal cancer; Vatalanib

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; VATALANIB;

ADJUVANT THERAPY; BLEEDING; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DIGESTIVE SYSTEM PERFORATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPERTENSION; METASTASIS; NEUROPATHY; PRESCRIPTION; REVIEW; THROMBOEMBOLISM; TREATMENT INDICATION; VOMITING;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III; COLORECTAL NEOPLASMS; HUMANS; HYPERTENSION; INTESTINAL PERFORATION; NEOVASCULARIZATION, PATHOLOGIC; PHTHALAZINES; PYRIDINES; THROMBOEMBOLISM; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOUND HEALING;

EID: 34548646676     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2007.0.348     Document Type: Review

References (30)

1. André T, Louvet C, de Gramont A, et le Gercor. Cancer du côlon : quoi de neuf en 2003? Bull Cancer 2004 ; 91 : 75-80.
2. Boige V, Malka D, Ducreux M. Implications thérapeutiques des inhibiteurs du VEGF dans le cancer colorectal. Bull Cancer 2005 ; 92 : S29-S36.
3. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005 ; 69(Suppl 3): 4-10.
4. Ferrara N. VEGF as a therapeutic target in cancer. Oncology 2005 ; 69(suppl 3): 11-6.
5. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil/leucovorin with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003 ; 21 : 60-5.
6. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004 ; 350 : 2335-42.
7. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer : results of a randomized phase II trial. J Clin Oncol 2005 ; 23 : 3697-705.
8. Kabbinavar FF, Hambleton J, Mass RD, et al. Combined analysis of efficacy : the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005 ; 23 : 3706-12.
9. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin : an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005 ; 23 : 3502-8.
10. Kopetz S, Abbruzzese JL, Eng C, et al. Preliminary results from phase II study of infusional 5FU, leucovorin, and irinotecan (Folfiri) plus bevacizumab as first treatment of metastatic colorectal cancer. Proc Am Soc Clin Oncol 2006 ; 165s : 3579a.
11. Sobrero A, Ackland S, Carrion P, et al. Efficacy and safety of bevacizumab in combination with irinotecan and infusional 5FU as first treatment of metastatic colorectal cancer. Proc Am Soc Clin Oncol 2006 ; 157s : 3544a.
12. Giantonio BJ, Catalano G, Meropol NJ, et al. High-dose bevacizumab omproves survival when combined with Folfox4 in previously treated advanced colorectal cancer : results from the Eastern Cooperative Group study (ECOG) E3200. Am Soc Clin Oncol 2005 ; 1S.
13. Giantonio BJ, Catalano G, O'Dwyer PJ, et al. Impact of bevacizumab dose reduction on clinical outcomes for patients treated on the Eastern Cooperative Group's Study E3200. Proc Am Soc Clin Oncol 2006 ; 156s : 3538a.
14. Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer : final analysis of the Tree study. Proc Am Soc Clin Oncol 2006 ; 148s : 3510a.
15. Cassidy J. First efficacy and safety results from Xelox-1/NO16966, a randomised 2x2 factorial phase III trial of Xelox vs Folfox4 + bevacizumab or placebo in first-line metastatic colorectal cancer. ESMO 2006 ; LBA3.
16. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with Xelox or Folfox4 : efficacy results from Xelox-1/NO16966, a randomized phase III trial in the first-line treatment of metastatic colorectal cancer. ASCO Gastrointestinal Cancers Symposim 2007, 204 : abst 238.
17. Kozloff M, Hainsworth J, Badarinath S, et al. Efficacy of bevacizumab plus chemotherapy as first line treatment of patients with metastatic colorectal cancer : updated results from a large observational regestry in US (Brite). Proc Am Soc Clin Oncol 2006 ; 155s : 3537a.
18. Kozloff M, Hainsworth J, Badarinath S, et al. Survival of patients with mCRC treated with bevacizumab in combination with chemotherapy : results from the Brite registry. Asco Gastrointestinal Cancers Symposim 2007 ; 271 (abst 375).
19. Hedrick E, Kozloff M. Hainsworth et al. Safety of bevacizumab plus chemotherapy as first line treatment of patients with metastatic colo-rectal cancer : updated results from a large observational regestry in US (Brite). Proc Am Soc Clin Oncol 2006 ; 155s : 35356a.
20. Berry S, Cunningham D, Lutiger M, et al. Preliminary safety of bevacizumab with first line Folfox, Capox, Folfiri and capecitabine for mCRC-first BEATtial. Proc Am Soc Clin Oncol 2006 ; 154s : 3534a.
21. Olszewski AJ, Grossbard ML, Kozuch PS. The horizon of antiangiogenic therapy for colorectal cancer. Oncology 2005 ; 19 : 297-306.
22. Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology 2005 ; 69(Suppl 3): 25-33.
23. Martel CL, Presant CA, Ebrahimi B, et al. Bevacizumab-related toxicities : association of hypertension and proteinuria. Community Oncology 2006 ; 3 : 90-3.
24. Sanborn RE, Sandler AB. The safety of bevacizumab. Expert Opin Drug Saf 2006 ; 5 : 289-301.
25. Sugrue M, Kozloff M, Hainsworth L, et al. Risk factors for gastrointestinal perforations in patients with metastatic colo-rectal cancer receiving bevacizumab plus chemotherapy. Proc Am Soc Clin Oncol 2006 ; 154s : 3535a.
26. Hecht JR, Ttarbach T, Jaeger E, et al. Randomized, double-blind, placebo-controlled, phase III study in patients with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxiplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (Confirm-1). J Clin Oncol 2005 ; 23 : 16S.
27. Koehne C, Bajetta E, Lin E, Van Custem E, et al. Results of an interim analysis of a multinational, double blind, phase III study in patients with previously treated metastatic colorectal cancer receiving Folfox4 and PTK787/ZK 222584 or placebo (Confirm 2). Proc Am Soc Clin Oncol 2006 ; 148s : 3508a.
28. Saltz LB, Lenz H, Hochster H, et al. Randomized phase II trial of cetuximab/bevacizumab/irinote-can vs cetuximab/bevacizumab in irinotecan-refractory colorectal cancer. Proc Am Soc Clin Oncol 2005 ; 24 : 3508a.
29. Segura C, Afchain P, de Gramont A, André T, pour le Gercor (French Oncology Research Group). Traitement adjuvant du cancer colique. Bull Cancer 2006 ; 1 : 683-90.
30. Willett CG, Boucher Y, Duda DG, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004 ; 10: 145-7.